| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | Honolulu Star-Advertiser (Reuters) |
| URL | staradvertiser.com/2026/07/18/breaking-news/doctors-question-evidence-behind-pentagon-plan-for-testosterone-screening (opens in a new tab) |
Specific Claim Evaluated
The Cleveland Clinic-led trial that led the FDA to remove a heart attack and stroke warning also found higher rates of atrial arrhythmia and bone fractures, and guidelines limit testosterone to confirmed deficiency with symptoms.
Primary Research Supporting or Contradicting the Claim
TRAVERSE showed noninferiority for major adverse cardiac events with more atrial fibrillation (Lincoff et al., 2023) and more clinical fractures with testosterone (Snyder et al., 2024). Guidelines limit treatment to men with symptoms and confirmed low testosterone (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article reports both reassuring and adverse trial findings, attributes concerns to named experts and accurately states guideline criteria.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs" - Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203-211. PMID
Supporting excerpt: "testosterone treatment did not result in a lower incidence of clinical fracture than placebo"